Back This Medical AI Tech
You don't often find healthcare tech company valued at $4M. HeartSciences is an exception. With $75M invested, including R&D, clinical trials, and product development, their patented AI software is approaching FDA submission, a potential major inflection point.
AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment
AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ivonescimab.
States brace for impact as Trump's big bill nears completion in Congress
JEFFERSON CITY, Mo. (AP) — President Donald Trump’s and reduce federal spending on some social safety net programs could have large implications for states, but for many it’s too late to do much about it this year.
Crypto Genius: These 5 Altcoins Could Crush Bitcoin in 2025 - Ad
On August 30th, two powerful "Wealth Drivers" ignite what could be a 2025 super bull run-backed by Trump. The altcoin market as a whole has already soared 132,721% over the past ten years and could surge again. A $900 stake could turn into $108K over 12 months. This is The Great Gain of 2025.
FDA vaccine official restricted COVID vaccine approvals against the advice of agency staff
WASHINGTON (AP) — The working under Health Secretary recently of two COVID-19 vaccines, disregarding recommendations from government scientists, according to federal documents released Wednesday.
GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning
FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of July 23 PDUFA decision.
A Robotics Leader in Disguise - Ad
Forget the hype. Real revenue, growing contracts, and a low float make this stock a hidden gem in the robotics space.
Ozempic, Mounjaro Users Cut $6.5 Billion From Grocery Bills: GLP-1 Boom Triggers Panic In Packaged Food Aisles
GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs altering consumer purchasing patterns.
Simulations Plus Sees Weaker Demand Persist, Outlook Softens
Simulations Plus Inc. reported lower than expected sales and reduced guidance due to cautious biopharma spending.
FDA Submission Expected This Summer - Invest Before It Happens - Ad
This company is making heart disease easier to detect with AI. Their tech has officially been designated a "Breakthrough" by the FDA. You now have an opportunity to get in at a potential inflection point.
Elmo's hacked X account posted racist messages. Sesame Workshop is trying to regain control
was trying to regain full control over its Elmo account on the X platform Monday after a hacker gained access and posted a string of racist and antisemitic messages.
Bill Gates Warns Of 'Devestating Effects' Of USAID Funding Cuts: 'It's Not Too Late To Reverse Them'
Bill Gates raises concerns over U.S. aid cuts' impact on HIV programs in Africa and calls for a reversal of the decision.
Copper's Rally Is Back. This $31M Junior Is Sitting on a Potential Fortune - Ad
A high-grade copper-gold discovery in Quebec just delivered extremely high grade intercepts. Valuation? Just $31M. With copper breaking out, the timing here could be perfect. Get the symbol here.
Chemical maker DuPont agrees to $27M settlement in polluted water lawsuit in upstate New York
HOOSICK FALLS, N.Y. (AP) — Chemical maker DuPont has agreed to a $27 million settlement to resolve a nearly decade-long lawsuit over the contamination of an upstate New York village's water supply.
Missouri governor repeals paid sick leave law approved last year by voters
JEFFERSON CITY, Mo. (AP) — Eight months after voters approved it, Missouri Gov. Mike Kehoe signed the repeal of a law Thursday that had guaranteed to workers and inflationary adjustments to the minimum wage.
Copper's Spiking - And This Junior Has the Grades to Match - Ad
Copper is climbing again - and this time, it looks tariff-proof. A $31M junior just posted nearly 1B lbs of copper equivalent. With insiders and institutions piling in, this could be the next breakout.
Rhythm Pharma's Oral Drug For Rare Obesity Shows Promise
Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 with regulators.
Mattel introduces its first Barbie with Type 1 diabetes
NEW YORK (AP) — Mattel has introduced its first Barbie representing a person with Type 1 diabetes, as part of wider efforts from the toy maker to increase inclusivity among its dolls.
Back This Medical AI Tech - Ad
You don't often find healthcare tech company valued at $4M. HeartSciences is an exception. With $75M invested, including R&D, clinical trials, and product development, their patented AI software is approaching FDA submission, a potential major inflection point.
Medical Groups Sue RFK Jr. For Assault On Science Over Unlawful COVID-19 Vaccine Rollbacks
Major health groups sue HHS and Robert F. Kennedy Jr. over COVID-19 vaccine policy changes for children and pregnant individuals.
Business News Digest
AP Business Digest
The Tesla Shock Nobody Sees Coming - Ad
While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
Business News Digest
AP Business Digest
Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial
Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B is ongoing.
What's inside Elon's building in Memphis will shock you - Ad
Inside Elon Musk's Memphis site lies a supercomputer built to power the world's first superhuman AI. It could make Elon a trillionaire - and new millionaires, too. With just $500, you could get in before the July 1st funding window closes.
Medicaid, food aid recipients worry about safety net cuts in bill sent to Trump
JEFFERSON CITY, Mo. (AP) — Supporters of the that Congress has sent to President Donald Trump say the changes to Medicaid, food aid and other programs will encourage personal responsibility and halt those scamming the system.
RSV vaccine access expanded to some people in their 50s, according to CDC website
The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following the advice of a recently fired panel of government vaccine advisers.
Elon's Greatest Invention... Hidden in South Memphis? - Ad
In South Memphis, I uncovered what could be Elon Musk's biggest invention yet. It's so secretive, rivals are flying drones to spy on it. If you're serious about investing in AI, now's the time to see what's really going on inside those walls.
Thinking about taking a stab at IV therapy? Ask some questions first
IV therapy clinics are springing up around the country, touting quick ways to recover from a hangover or a hard workout. But doctors and regulators preach caution.
Severe heat waves hit Southern Europe as local authorities warn against wildfire risks
ROME (AP) — Major heat waves across Southern Europe have pushed temperatures above 40 C (104 F) in countries including Italy, Spain and Greece, as local authorities issued fresh warnings against the risk of wildfires.
The Public Safety Revolution - Ad
Robotics is transforming public safety. One company is leading the charge with cutting-edge tech and a low-cost service model. With growing momentum and a tight stock float, this is one to watch.
The Senate is putting Trump's big bill back on track but hurdles remain
WASHINGTON (AP) — Senate Republicans appeared Friday to push back on track after a flurry of last-minute revisions, including , but there's still a long way to go ahead of expected weekend votes.
RFK Jr's CDC Panel Recommends Merck's RSV Shot For Infants
CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in clinical trials.
Crypto Genius: These 5 Altcoins Could Crush Bitcoin in 2025 - Ad
On August 30th, two powerful "Wealth Drivers" ignite what could be a 2025 super bull run-backed by Trump. The altcoin market as a whole has already soared 132,721% over the past ten years and could surge again. A $900 stake could turn into $108K over 12 months. This is The Great Gain of 2025.
No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall
Edgewise reports sustained functional stability in Becker patients and selects Phase 3 dose for Duchenne after positive Phase 2 trial data.
States can cut off Medicaid funding to Planned Parenthood, the Supreme Court rules
WASHINGTON (AP) — A divided allowed states to cut off Medicaid money to Planned Parenthood in a ruling handed down Thursday amid a wider Republican-backed push to defund the country’s biggest abortion provider.
A Robotics Leader in Disguise - Ad
Forget the hype. Real revenue, growing contracts, and a low float make this stock a hidden gem in the robotics space.
Evotec's Collaboration Sparks Hope For Acute Kidney Injury Breakthroughs
Evotec shares rise after joining NURTuRE-AKI to advance kidney disease research through molecular data integration.
Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges
Amarin signs $175 million Vazkepa deal with Recordati, plans global restructuring and targets $70 million in cost cuts to improve cash flow
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.